Regorafenib - Bayer Healthcare
At a glance
- Drug Originator Bayer HealthCare
- Drug Class Amides; Antineoplastics; Eye disorder therapies; Fluorobenzenes; Phenylurea compounds; Pyridines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Mitogen-activated-protein kinase 11-inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Raf kinase inhibitors; Receptor protein-tyrosine kinase antagonists; TIE 2 receptor antagonists; TrkA receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
- USA Patent Applicants BAYER HLTHCARE
- USA Patents 7
- NDAs 1
- International Patents 167
- Patent Applications 2,998
Table of Contents

Disclaimer